Within the context of breast cancer, we commonly discuss the oncogenic role of amplification of HER2 and its use as an indicator of more aggressive tumor phenotypes that benefits from targeted therapies (i.e., trastuzumab) 34, 35, 36. The gene discussed is ERBB2; the disease is breast carcinoma.